

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*This announcement is for information purpose only and does not constitute an invitation or offer to acquire, purchase or subscribe for any securities of the Company.*



## **HUAKANG BIOMEDICAL HOLDINGS COMPANY LIMITED**

**華康生物醫學控股有限公司**

*(Incorporated in Cayman Islands with limited liability)*

**(Stock Code: 8622)**

### **SUPPLEMENTAL ANNOUNCEMENT PLACING OF NEW SHARES UNDER GENERAL MANDATE**

#### **Placing Agent**



長雄證券有限公司  
EVER-LONG SECURITIES COMPANY LIMITED

Reference is made to the announcement of Huakang Biomedical Holdings Company Limited (the “**Company**”) dated 29 July 2022 (the “**Announcement**”) in respect of the Placing. Unless defined otherwise, capitalised terms used herein shall have the same meanings as those defined in the Announcement.

According to the Announcement, in the event that any of the conditions of the Placing is not satisfied and/or waived in whole or in part by the Placing Agent prior to 12:00 noon on or before the Long Stop Date (i.e. 26 August 2022) or such later date to be agreed between the Company and the Placing Agent in writing, the Placing will be terminated and the Placing will not proceed and all obligations and liabilities of the parties to the Placing Agreement will cease and determine and no party will have any claim against the others (save for any antecedent breaches).

The Company considers that a longer placing period may encounter a higher risk of share price fluctuation which may cause a significant discount on the Placing Price. As such, the Company decided to shorten the placing period to expedite the Placing and minimize such risk. On 5 August 2022 (after trading hours), the Company and the Placing Agent entered into a supplemental placing agreement (the “**Supplemental Placing Agreement**”) to revise the Long Stop Date to 19 August 2022 (or such later date to be agreed between the Company and the Placing Agent in writing).

Subject to the Listing Committee granting or agreeing to grant the listing of and permission to deal in the Placing Shares, the Placing is currently expected to be completed by 25 August 2022.

The Board considers that the revision of the Long Stop Date under the Supplemental Placing Agreement would be in the interests of the Company and the Shareholders as a whole. Save and except for the aforesaid revision of the Long Stop Date, all other terms of the Placing Agreement remain unchanged.

**Shareholders and potential investors should note that the Completion is subject to conditions under the Placing Agreement to be fulfilled. As the Placing may or may not proceed, Shareholders and potential investors are reminded to exercise caution when dealing in the Shares.**

By Order of the Board  
**Huakang Biomedical Holdings Company Limited**  
**Zhang Shuguang**  
Chairman and Executive Director

Hong Kong, 5 August 2022

*As at the date of this announcement, the executive Directors are Mr. Zhang Shuguang, Mr. Zhang Chunguang, Mr. Poon Lai Yin Michael and Mr. He Jiaming; and the independent non-executive Directors are Dr. Chow Kwok Fai Joseph, Dr. Cheng Faat Ting Gary and Mr. Chan Kin Sang.*

*This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief, the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.*

*This announcement will remain on the “Latest Company Announcements” page of the Stock Exchange website at [www.hkexnews.hk](http://www.hkexnews.hk) for at least seven days from the date of publication and on the Company’s website at [www.huakangbiomedical.com](http://www.huakangbiomedical.com).*